Biomarkers of scleroderma lung disease: Recent progress

Current Rheumatology Reports

Volumn 13, Issue 1, 2011, Pages 44-50

  Hant, Faye N ^a   Silver, Richard M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

APRIL; BAFF; Biomarkers; Exhaled nitric oxide; Interstitial lung disease; KL 6; PMN elastase; Scleroderma; SP D; Systemic sclerosis; TWEAK

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; ELASTASE; KREBS VON DEN LUNGEN 6 ANTIGEN; NITRIC OXIDE; RANTES; SURFACTANT PROTEIN D; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ARTICLE; CYTOKINE RELEASE; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE MARKER; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG FUNCTION TEST; NEUTROPHIL; NON INVASIVE MEASUREMENT; NONHUMAN; PATIENT MONITORING; PULMONARY HYPERTENSION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

BIOLOGICAL MARKERS; HUMANS; LUNG DISEASES; SCLERODERMA, SYSTEMIC;

EID: 79551543456     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0143-9     Document Type: Article

References (52)

1. Mayes MD, Reveille JD: Epidemiology, demographics and genetics. In Systemic Sclerosis, edn 2. Edited by Clements PJ, Furst DE. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:1-15.
2. J Varga 2008 Systemic sclerosis: an update Bull NYU Hosp Jt Dis 66 198 202 18937632
3. MB Kinsella EA Smith KS Miller, et al. 1989 Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma Arthritis Rheum 32 577 583 1:STN:280:DyaL1M3ks1Kitg%3D%3D 10.1002/anr.1780320511 2719731 (Pubitemid 19146698)
4. A Ludwicka M Trojanowska EA Smith, et al. 1992 Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of patients with scleroderma J Rheumatol 19 1716 1723 1:STN:280:DyaK3s7kvVamsw%3D%3D 1491389
5. RM Silver JF Metcalf JH Stanley, et al. 1984 Interstitial lung disease in scleroderma Analysis by bronchoalveolar lavage. Arthritis Rheum 27 1254 1262 1:STN:280:DyaL2M%2Fks1Kguw%3D%3D
6. A Ludwicka T Ohba M Trojanowska, et al. 1995 Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma J Rheumatol 22 1876 1883 1:CAS:528:DyaK2MXpsVWjsbY%3D 8991985
7. MB Bolster A Ludwicka SE Sutherland, et al. 1997 Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis Arthritis Rheum 40 743 751 1:STN:280:DyaK2s3ksVeisg%3D%3D 10.1002/art.1780400422 9125259 (Pubitemid 27157582)
8. GS Bogatkevich E Tourkina RM Silver, et al. 2001 Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway J Biol Chem 276 45184 45192 1:CAS:528:DC%2BD3MXovFensLs%3D 10.1074/jbc.M106441200 11579091
9. SE Orfanos E Psevdi N Stratigis, et al. 2001 Pulmonary capillary endothelial dysfunction in early systemic sclerosis Arthritis Rheum 44 902 911 1:CAS:528:DC%2BD3MXpt12ltbk%3D 10.1002/1529-0131(200104)44:4<902::AID- ANR147>3.0.CO;2-9 11315930 (Pubitemid 32319783)
10. A Nakano E Yamaguchi S Naitoh, et al. 1992 Assessment of alveolar epithelial permeability in progressive systemic sclerosis (PSS) using 99mTc-DTPA (diethylene triamine penta acetate) aerosol inhalation Nihon Kyobu Shikkan Gakkai Zasshi 30 45 50 1:STN:280:DyaK38zis1amsQ%3D%3D 1625395
11. NK Harrison AR Myers B Corrin, et al. 1991 Structural features of interstitial lung disease in systemic sclerosis Am Rev Respir Dis 144 706 713 1:STN:280:DyaK3MzmvFSnuw%3D%3D 1892314
12. S Imokawa A Sato H Hayakawa, et al. 1997 Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis Am J Respir Crit Care Med 156 631 636 1:STN:280:DyaK2svisFajsg%3D%3D 9279250
13. E Crouch JR Wright 2001 Surfactant proteins a and d and pulmonary host defense Annu Rev Physiol 63 521 554 1:CAS:528:DC%2BD3MXjtFKmtbo%3D 10.1146/annurev.physiol.63.1.521 11181966 (Pubitemid 32304328)
14. EC Crouch 2000 Surfactant protein-D and pulmonary host defense Respir Res 1 93 108 1:CAS:528:DC%2BD3MXosVarsb0%3D 10.1186/rr19 11667972 (Pubitemid 34187899)
15. Y Honda Y Kuroki E Matsuura, et al. 1995 Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids Am J Respir Crit Care Med 152 1860 1866 1:STN:280:DyaK28%2FpsVahuw%3D%3D 8520747
16. KE Greene JR Wright KP Steinberg, et al. 1999 Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS Am J Respir Crit Care Med 160 1843 1850 1:STN:280:DC%2BD3c%2Fls1ehsg%3D%3D 10588595
17. Y Kuroki H Takahashi H Chiba, et al. 1998 Surfactant proteins A and D: disease markers Biochim Biophys Acta 1408 334 345 1:CAS:528:DyaK1cXnt1artb8%3D 9813383
18. Y Asano H Ihn K Yamane, et al. 2001 Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis Arthritis Rheum 44 1363 1369 1:STN:280:DC%2BD3MzksVOnsQ%3D%3D 10.1002/1529-0131(200106)44:6<1363::AID-ART229>3.0.CO;2-5 11407696 (Pubitemid 32537535)
19. N Kohno Y Awaya T Oyama, et al. 1993 KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease Am Rev Respir Dis 148 637 642 1:STN:280:DyaK3sznvVWqtQ%3D%3D 8368634
20. FN Hant A Ludwicka-Bradley HJ Wang, et al. 2009 Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma J Rheumatol 36 773 780 1:CAS:528:DC%2BD1MXkvFemt7c%3D 10.3899/jrheum.080633 19286849
21. DP Tashkin R Elashoff PJ Clements, et al. 2006 Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 354 2655 2666 1:CAS:528:DC%2BD28XmtFSgtLs%3D 10.1056/NEJMoa055120 16790698
22. K Yanaba M Hasegawa K Takehara, et al. 2004 Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis J Rheumatol 31 1112 1120 1:CAS:528:DC%2BD2cXlsFWgt74%3D 15170923
23. TS Zheng LC Burkly 2008 No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies J Leukoc Biol 84 338 347 1:CAS:528:DC%2BD1cXptF2htrw%3D 10.1189/jlb.0308165 18483204
24. MC Park SJ Chung YB Park, et al. 2008 Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis Scand J Rheumatol 37 173 178 1:CAS:528:DC%2BD1cXnsVyqsLg%3D 10.1080/03009740801898608 18465450 (Pubitemid 351874000)
25. Z Zhao LC Burkly S Campbell, et al. 2007 TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus J Immunol 179 7949 7958 1:CAS:528:DC%2BD2sXhtlajt7bI 18025243
26. M Bielecki K Kowal A Lapinska, et al. 2009 Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis Folia Histochem Cytobiol 47 465 469 10.2478/v10042-009-0103-2 20164033
27. •• Yanaba K, Yoshizaki A, Muroi E, et al.: Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis. J Rheumatol 2009, 36:1657-1662. This study provides the first report of increased TWEAK levels in patients with SSc and highlights potential mechanisms for the protective effect of TWEAK against the development of PF in SSc patients.
28. V Appay SL Rowland-Jones 2001 RANTES: a versatile and controversial chemokine Trends Immunol 22 83 87 1:CAS:528:DC%2BD3MXhvVKhsro%3D 10.1016/S1471-4906(00)01812-3 11286708 (Pubitemid 32667526)
29. A Zlotnik O Yoshie 2000 Chemokines: a new classification system and their role in immunity Immunity 12 121 127 1:CAS:528:DC%2BD3cXhslKqsL8%3D 10.1016/S1074-7613(00)80165-X 10714678
30. E Saito M Fujimoto M Hasegawa, et al. 2002 CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse J Clin Invest 109 1453 1462 1:CAS:528:DC%2BD38XktlWlu7s%3D 12045259
31. S Sato M Fujimoto M Hasegawa, et al. 2004 Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells Arthritis Rheum 50 1918 1927 10.1002/art.20274 15188368 (Pubitemid 38725103)
32. F Mackay JL Browning 2002 BAFF: a fundamental survival factor for B cells Nat Rev Immunol 2 465 475 1:CAS:528:DC%2BD38XkvFKks74%3D 10.1038/nri844 12094221
33. F Mackay SL Kalled 2002 TNF ligands and receptors in autoimmunity: an update Curr Opin Immunol 14 783 790 1:CAS:528:DC%2BD38Xot1agtLg%3D 10.1016/S0952-7915(02)00407-7 12413530 (Pubitemid 35292427)
34. T Matsushita M Hasegawa K Yanaba, et al. 2006 Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes Arthritis Rheum 54 192 201 1:CAS:528: DC%2BD28XhsVensLo%3D 10.1002/art.21526 16385515 (Pubitemid 43122202)
35. T Matsushita M Fujimoto M Hasegawa, et al. 2007 Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF J Rheumatol 34 2056 2062 1:CAS:528:DC%2BD2sXht1ylurzI 17896803
36. P Failli L Palmieri C D'Alfonso, et al. 2002 Effect of N-acetyl-L-cysteine on peroxynitrite and superoxide anion production of lung alveolar macrophages in systemic sclerosis Nitric Oxide 7 277 282 1:CAS:528:DC%2BD38XoslGnu74%3D 10.1016/S1089-8603(02)00120-9 12446176 (Pubitemid 35365672)
37. RE Girgis MK Gugnani J Abrams, et al. 2002 Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease Am J Respir Crit Care Med 165 1587 1591 10.1164/rccm.2104003 12070057 (Pubitemid 34693936)
38. KP Tiev J Coste M Ziani, et al. 2009 Diagnostic value of exhaled nitric oxide to detect interstitial lung disease in systemic sclerosis Sarcoidosis Vasc Diffuse Lung Dis 26 32 38 1:STN:280:DC%2BD1MfgsVOnsg%3D%3D 19960786
39. KP Tiev J Cabane F Aubourg, et al. 2007 Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide Eur Respir J 30 26 30 1:CAS:528:DC%2BD2sXpt1aguro%3D 10.1183/09031936.00129806 17428812 (Pubitemid 47074002)
40. KP Tiev NN Le-Dong S Duong-Quy, et al. 2009 Exhaled nitric oxide, but not serum nitrite and nitrate, is a marker of interstitial lung disease in systemic sclerosis Nitric Oxide 20 200 206 1:CAS:528:DC%2BD1MXjt1ahsbc%3D 10.1016/j.niox.2008.11.004 19100854
41. F Chua GJ Laurent 2006 Neutrophil elastase: mediator of extracellular matrix destruction and accumulation Proc Am Thorac Soc 3 424 427 1:CAS:528:DC%2BD28XntF2ltL8%3D 10.1513/pats.200603-078AW 16799086 (Pubitemid 44033357)
42. Y Zhu X Liu CM Skold, et al. 2001 Collaborative interactions between neutrophil elastase and metalloproteinases in extracellular matrix degradation in three-dimensional collagen gels Respir Res 2 300 305 1:CAS:528: DC%2BD3MXosVajs78%3D 10.1186/rr73 11686900 (Pubitemid 34189655)
43. F Chua SE Dunsmore PH Clingen, et al. 2007 Mice lacking neutrophil elastase are resistant to bleomycin-induced pulmonary fibrosis Am J Pathol 170 65 74 1:CAS:528:DC%2BD2sXhsV2gtbY%3D 10.2353/ajpath.2007.060352 17200183 (Pubitemid 47339190)
44. SE Dunsmore J Roes FJ Chua, et al. 2001 Evidence that neutrophil elastase-deficient mice are resistant to bleomycin-induced fibrosis Chest 120 1 Suppl 35S 36S 1:STN:280:DC%2BD3MvgtVCnsA%3D%3D 10.1378/chest.120.1-suppl.S35 11451907 (Pubitemid 32702132)
45. •• Hara T, Ogawa F, Yanaba K, et al.: Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 2009, 36:99-105. This study highlights a potential novel serologic marker for SSc-ILD, PMN elastase, showing this biomarker to be increased in patients with SSc, especially those with ILD. It also highlights that PMN elastase positively correlated with SP-D and KL-6, two biomarkers shown in several studies to correlate with pulmonary disease in SSc patients.
46. J Cooley B McDonald FJ Accurso, et al. 2008 Patterns of neutrophil serine protease-dependent cleavage of surfactant protein D in inflammatory lung disease J Leukoc Biol 83 946 955 1:CAS:528:DC%2BD1cXkt1agsL4%3D 10.1189/jlb.1007684 18211966 (Pubitemid 351959875)
47. TO Hirche EC Crouch M Espinola, et al. 2004 Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain J Biol Chem 279 27688 27698 1:CAS:528:DC%2BD2cXkvFGnurk%3D 10.1074/jbc.M402936200 15078883 (Pubitemid 38812610)
48. C Baldini L Giusti L Bazzichi, et al. 2008 Association of psoriasin (S100A7) with clinical manifestations of systemic sclerosis: is its presence in whole saliva a potential predictor of pulmonary involvement? J Rheumatol 35 1820 1824 1:CAS:528:DC%2BD1cXhtFyqtbjI 18634149
49. K Komura K Yanaba F Ogawa, et al. 2008 Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody Clin Exp Dermatol 33 329 332 1:STN:280:DC%2BD1c3lvVejtw%3D%3D 10.1111/j.1365-2230.2007. 02678.x 18312458 (Pubitemid 351550653)
50. G Kumanovics T Minier J Radics, et al. 2008 Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis Clin Exp Rheumatol 26 414 420 1:STN:280: DC%2BD1cvhtVaqsQ%3D%3D 18578962
51. A Volpe D Biasi P Caramaschi, et al. 2006 Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features Rheumatology (Oxford) 45 314 320 1:CAS:528:DC%2BD28Xhs1SksbY%3D 10.1093/rheumatology/kei151 (Pubitemid 43372847)
52. K Yanaba A Yoshizaki E Muroi, et al. 2010 CCL13 is a promising diagnostic marker for systemic sclerosis Br J Dermatol 162 332 336 1:CAS:528: DC%2BC3cXis1Wlt78%3D 10.1111/j.1365-2133.2009.09507.x 19747218